Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in: Current Cardiology Reports 11/2023

09-10-2023 | Fibrates | Lipid Abnormalities and Cardiovascular Prevention (ED Michos, Section Editor)

Should We “RESPECT EPA” More Now? EPA and DHA for Cardiovascular Risk Reduction

Authors: Michelle D. Kelsey, Neha J. Pagidipati

Published in: Current Cardiology Reports | Issue 11/2023

Login to get access

Abstract

Purpose of Review

There has been much debate surrounding the use of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), for cardiovascular (CV) risk reduction.

Recent Findings

Recent trials of EPA and DHA have offered conflicting evidence. Some demonstrate reduction in CV risk using EPA alone in select populations. Others have demonstrated no benefit, with potential for side effects, such as new-onset atrial fibrillation.

Summary

Both EPA and DHA have favorable impact on lipids and inflammation, suggesting some biological plausibility for CV risk reduction. However, clinical trials of these agents have produced mixed results. Based on available evidence, EPA may work better for CV risk than DHA and EPA combined. The benefit of EPA seems to be dose dependent, though higher doses may have more side effects. Further research is needed to define the role of EPA and DHA in the landscape of CV risk reduction.
Literature
1.
Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16(1):149.PubMedPubMedCentralCrossRef
2.
3.
Domenichiello AF, Kitson AP, Bazinet RP. Is docosahexaenoic acid synthesis from α-linolenic acid sufficient to supply the adult brain? Prog Lipid Res. 2015;59:54–66.PubMedCrossRef
4.
Miller MR, Nichols PD, Carter CG. n-3 oil sources for use in aquaculture–alternatives to the unsustainable harvest of wild fish. Nutr Res Rev. 2008;21(2):85–96.PubMedCrossRef
5.
Cladis DP, Kleiner AC, Freiser HH, Santerre CR. Fatty acid profiles of commercially available finfish fillets in the United States. Lipids. 2014;49(10):1005–18.PubMedCrossRef
6.
Sprague M, Dick JR, Tocher DR. Impact of sustainable feeds on omega-3 long-chain fatty acid levels in farmed Atlantic salmon, 2006–2015. Sci Rep. 2016;6:21892.PubMedPubMedCentralCrossRef
7.
Van Elswyk ME, McNeill SH. Impact of grass/forage feeding versus grain finishing on beef nutrients and sensory quality: the U.S. experience. Meat Sci. 2014;96(1):535–40.PubMedCrossRef
8.
Dyerberg J, Madsen P, Møller JM, Aardestrup I, Schmidt EB. Bioavailability of marine n-3 fatty acid formulations. Prostaglandins Leukot Essent Fatty Acids. 2010;83(3):137–41.PubMedCrossRef
9.
Parker HM, Johnson NA, Burdon CA, Cohn JS, O’Connor HT, George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;56(4):944–51.PubMedCrossRef
10.
Maki KC, Bays HE, Dicklin MR, Johnson SL, Shabbout M. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol. 2011;5(6):483–92.PubMedCrossRef
11.
Dejager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res. 1993;34(2):295–308.PubMedCrossRef
12.
Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014;27(7):885–96.PubMedPubMedCentralCrossRef
13.
Wu S, Zhu C, Wang Z, Wang S, Yuan P, Song T, et al. Effects of fish oil supplementation on cardiometabolic risk factors in overweight or obese children and adolescents: a meta-analysis of randomized controlled trials. Front Pediatr. 2021;9:604469.PubMedPubMedCentralCrossRef
14.
Harris WS, Rambjør GS, Windsor SL, Diederich D. n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans. Am J Clin Nutr. 1997;65(2):459–64.PubMedCrossRef
15.
Kenny D, Warltier DC, Pleuss JA, Hoffmann RG, Goodfriend TL, Egan BM. Effect of omega-3 fatty acids on the vascular response to angiotensin in normotensive men. Am J Cardiol. 1992;70(15):1347–52.PubMedCrossRef
16.
Chin JP, Gust AP, Nestel PJ, Dart AM. Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans. Hypertension. 1993;21(1):22–8.PubMedCrossRef
17.
McVeigh GE, Brennan GM, Cohn JN, Finkelstein SM, Hayes RJ, Johnston GD. Fish oil improves arterial compliance in non-insulin-dependent diabetes mellitus. Arterioscler Thromb. 1994;14(9):1425–9.PubMedCrossRef
18.
Nodari S, Triggiani M, Campia U, Manerba A, Milesi G, Cesana BM, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2011;57(7):870–9.PubMedCrossRef
19.
Ghio S, Scelsi L, Latini R, Masson S, Eleuteri E, Palvarini M, et al. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail. 2010;12(12):1345–53.PubMedCrossRef
20.
Mozaffarian D, Gottdiener JS, Siscovick DS. Intake of tuna or other broiled or baked fish versus fried fish and cardiac structure, function, and hemodynamics. Am J Cardiol. 2006;97(2):216–22.PubMedCrossRef
21.
Oikonomou E, Vogiatzi G, Karlis D, Siasos G, Chrysohoou C, Zografos T, et al. Effects of omega-3 polyunsaturated fatty acids on fibrosis, endothelial function and myocardial performance, in ischemic heart failure patients. Clin Nutr. 2019;38(3):1188–97.PubMedCrossRef
22.
Grimsgaard S, Bønaa KH, Hansen JB, Myhre ES. Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans. Am J Clin Nutr. 1998;68(1):52–9.PubMedCrossRef
23.
24.
Sellmayer A, Witzgall H, Lorenz RL, Weber PC. Effects of dietary fish oil on ventricular premature complexes. Am J Cardiol. 1995;76(12):974–7.PubMedCrossRef
25.
Fatkin D, Cox CD, Martinac B. Fishing for links between omega-3 fatty acids and atrial fibrillation. Circulation. 2022;145(14):1037–9.PubMedCrossRef
26.
Vors C, Allaire J, Mejia SB, Khan TA, Sievenpiper JL, Lamarche B. Comparing the effects of docosahexaenoic and eicosapentaenoic acids on inflammation markers using pairwise and network meta-analyses of randomized controlled trials. Adv Nutr. 2021;12(1):128–40.PubMedCrossRef
27.
O’Mahoney LL, Matu J, Price OJ, Birch KM, Ajjan RA, Farrar D, et al. Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials. Cardiovasc Diabetol. 2018;17(1):98.PubMedPubMedCentralCrossRef
28.
Xu T, Sun Y, Sun W, Yao L, Sun L, Liu L, et al. Effect of omega-3 fatty acid supplementation on serum lipids and vascular inflammation in patients with end-stage renal disease: a meta-analysis. Sci Rep. 2016;6:39346.PubMedPubMedCentralCrossRef
29.
Morvaridzadeh M, Sepidarkish M, Yavari M, Tahvilian N, Heydarian A, Khazdouz M, et al. The effects of omega-3 fatty acid supplementation on inflammatory factors in HIV-infected patients: a systematic review and meta-analysis of randomized clinical trials. Cytokine. 2020;136:155298.PubMedCrossRef
30.
Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. In: Draper HH, editor. Advances in nutritional research. Boston, MA: Springer, US; 1980. p. 1–22.
31.
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8.PubMedCrossRef
32.
Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23–32.PubMedCrossRef
33.
ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379(16):1540–50.CrossRef
34.
•• Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2018;380(1):11–22. This trial showed improvement in cardiovascular outcomes with high-dose EPA in individuals with prior history of cardiovascular disease or at high risk.PubMedCrossRef
35.
•• Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268–80. This trial showed no different in cardiovascular outcomes with use of combined EPA and DHA among individuals with prior history of cardiovascular disease or at high risk.PubMedPubMedCentralCrossRef
36.
Bostrom JA, Beckman JA, Berger JS. Summoning STRENGTH to question the placebo in REDUCE-IT. Circulation. 2021;144(6):407–9.PubMedCrossRef
37.
Doi T, Langsted A, Nordestgaard BG. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. Eur Heart J. 2021;42(47):4807–17.PubMedCrossRef
38.
Maki KC. Investigating contrasting results in REDUCE-IT and STRENGTH: partial answers but questions remain. Eur Heart J. 2021;42(47):4818–20.PubMedCrossRef
39.
Pirillo A, Catapano AL. Omega-3 for cardiovascular diseases: where do we stand after REDUCE-IT and STRENGTH? Circulation. 2021;144(3):183–5.PubMedCrossRef
40.
Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, et al. Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1β, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy. Circulation. 2022;146(5):372–9.PubMedCrossRef
41.
Li Y, Hruby A, Bernstein AM, Ley SH, Wang DD, Chiuve SE, et al. Saturated fats compared with unsaturated fats and sources of carbohydrates in relation to risk of coronary heart disease: a prospective cohort study. J Am Coll Cardiol. 2015;66(14):1538–48.PubMedPubMedCentralCrossRef
42.
Wang Q, Afshin A, Yakoob MY, Singh GM, Rehm CD, Khatibzadeh S, et al. Impact of nonoptimal intakes of saturated, polyunsaturated, and trans fat on global burdens of coronary heart disease. J Am Heart Assoc. 2016;5(1):e002891.PubMedPubMedCentralCrossRef
43.
Itakura H, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, et al. Relationships between plasma fatty acid composition and coronary artery disease. J Atheroscler Thromb. 2011;18(2):99–107.PubMedCrossRef
44.
Nishizaki Y, Miyauchi K, Iwata H, Inoue T, Hirayama A, Kimura K, et al. Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study. Am Heart J. 2023;257:1–8.PubMedCrossRef
45.
Nelson JR, Raskin S. The eicosapentaenoic acid:arachidonic acid ratio and its clinical utility in cardiovascular disease. Postgrad Med. 2019;131(4):268–77.PubMedCrossRef
46.
•• Daida H. Randomized trial for evaluation in secondary prevention efficacy of combination therapy–statin and eicosapentaenoic acid - RESPECT-EPA. American Heart Association Scientific Sessions; 6 November; Chicago, IL. 2022. This trial studied the impact of high-dose EPA on cardiovascular outcomes. Although this study may have been underpowered and did not meet its primary endpoint, it lends insight into populations that may derive benefit from treatment with EPA.
47.
Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3(3):Cd003177.PubMed
48.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168–209.PubMedCrossRef
49.
Virani SS, Morris PB, Agarwala A, Ballantyne CM, Birtcher KK, Kris-Etherton PM, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia. J Am Coll Cardiol. 2021;78(9):960–93.PubMedCrossRef
50.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–232.PubMedPubMedCentralCrossRef
51.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes—2023. Diabetes Care. 2022;46(Supplement_1):S158–90.PubMedCentralCrossRef
52.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 5. Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes—2023. Diabetes Care. 2022;46(Supplement_1):S68–96.PubMedCentralCrossRef
53.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227–337.PubMedCrossRef
54.
Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13(6):860–72.PubMedCrossRef
55.
Kirkpatrick CF, Sikand G, Petersen KS, Anderson CAM, Aspry KE, Bolick JP, et al. Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association. J Clin Lipidol. 2023.
Metadata
Title
Should We “RESPECT EPA” More Now? EPA and DHA for Cardiovascular Risk Reduction
Authors
Michelle D. Kelsey
Neha J. Pagidipati
Publication date
09-10-2023
Publisher
Springer US
Keyword
Fibrates
Published in
Current Cardiology Reports / Issue 11/2023
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01972-w

Other articles of this Issue 11/2023

Current Cardiology Reports 11/2023 Go to the issue

Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

How much resistance exercise is needed to improve CV health?

Interventional Cardiology (SR Bailey and T Helmy, Section Editors)

Coronary Angiography Complicated by Acute Ischaemic Stroke and the Use of Thrombolysis: a Cardiology Perspective and Narrative Review of Current Literature

Valvular Heart Disease (TL Kiefer, Section Editor)

TAVR in TAVR: Where Are We in 2023 for Management of Failed TAVR Valves?

Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

Body Fat Distribution, Diabetes Mellitus, and Cardiovascular Disease: an Update

Women and Cardiovascular Health (N Goldberg and S Lewis, Section Editors)

Tailored to a Woman’s Heart: Gender Cardio-Oncology Across the Lifespan

Pericardial Disease (AL Klein and CL Jellis, Section Editors)

CT–guided pericardiocentesis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits